PrEP does not prevent any STI other than HIV. The medications in PrEP are designed to block HIV replication specifically, and they have zero effect on bacteria like chlamydia, gonorrhea, and syphilis or on other viruses like HPV and herpes. However, being on PrEP comes with a built-in benefit: regular STI screening that can catch infections you might not know you have.
Why PrEP Only Works Against HIV
PrEP medications (sold under brand names like Truvada and Descovy) contain antiretroviral drugs that block an enzyme called reverse transcriptase, which HIV needs to copy itself inside your cells. When these drugs are already present in your bloodstream and tissues at the time of exposure, the virus can’t replicate and the infection is stopped before it takes hold. This is why PrEP is over 95% effective at preventing HIV when taken consistently.
Bacterial STIs like gonorrhea, chlamydia, and syphilis are entirely different organisms. They don’t use reverse transcriptase or any of the machinery that antiretrovirals target. The same goes for viral STIs like HPV, herpes, and hepatitis B, which replicate through different pathways than HIV. Taking PrEP gives your body no additional defense against any of these infections.
STI Rates Can Actually Rise on PrEP
Research has consistently shown that people starting PrEP often see an increase in STI diagnoses. One study comparing the 12 months before and after PrEP initiation found STI rates roughly 72% higher in the period after starting PrEP. Even compared to people who sought post-exposure prophylaxis (PEP) after a single high-risk encounter, PrEP users had significantly higher STI rates.
The likely explanation is something called risk compensation. Before PrEP, many people used multiple strategies to reduce their risk: condoms, choosing partners based on perceived HIV status, limiting the number of partners, or being selective about the type of sex they had. Once PrEP removed the fear of HIV, some people relaxed one or more of those other strategies. That shift in behavior doesn’t change PrEP’s effectiveness against HIV, but it can open the door to bacterial and viral STIs that condoms would have helped prevent.
The Screening Benefit of Being on PrEP
One of the underappreciated advantages of PrEP is that it keeps you connected to regular healthcare. CDC guidelines require STI screening at every follow-up visit, and the schedule is frequent. For men who have sex with men and transgender women, bacterial STI testing happens every three to four months. All PrEP users are screened for syphilis and gonorrhea at least every six months. Chlamydia screening is recommended every six to twelve months depending on your risk factors and sexual partners.
Many STIs, particularly chlamydia, gonorrhea (especially in the throat and rectum), and early syphilis, produce no symptoms at all. Without routine screening, these infections can go undetected for months, leading to complications and unknowing transmission to partners. People on PrEP are far more likely to have these silent infections caught and treated early than people who only visit a clinic when symptoms appear.
Doxy-PEP: A New Tool for Bacterial STIs
Since PrEP doesn’t cover bacterial STIs, a newer strategy called doxy-PEP has emerged to fill that gap. It involves taking 200 mg of doxycycline, a common antibiotic, within 72 hours after sex. In three large clinical trials, this approach reduced syphilis and chlamydia infections by more than 70% and gonorrhea infections by about 50%.
The CDC now recommends that providers offer doxy-PEP to gay, bisexual, and other men who have sex with men and transgender women who have had at least one bacterial STI in the past 12 months. It’s a single dose taken as soon as possible after sex, with a maximum of 200 mg in any 24-hour period. Doxy-PEP isn’t a replacement for condoms or screening, but it adds a meaningful layer of protection against the bacterial infections that PrEP can’t touch.
Vaccines Cover Some of the Gaps
Several STIs that PrEP doesn’t prevent are vaccine-preventable. If you’re on PrEP or considering it, these are worth discussing at your next visit:
- HPV: The 9-valent HPV vaccine (Gardasil 9) protects against the strains most likely to cause genital warts and cancers of the cervix, anus, and throat. It’s routinely recommended through age 26, with shared decision-making for people 27 to 45 who weren’t previously vaccinated.
- Hepatitis B: Hepatitis B spreads through the same sexual and blood-borne routes as HIV. The preferred vaccine schedule is two doses given four weeks apart.
- Hepatitis A: Spread through oral-anal contact, hepatitis A is preventable with a two-dose vaccine series given six to eighteen months apart.
- Mpox: The JYNNEOS vaccine is recommended for people who have or anticipate potential exposure, given as two doses 28 days apart.
Condoms Still Matter
PrEP is extraordinarily effective at its one job: stopping HIV. For everything else, condoms remain the broadest-spectrum protection available during sex. They significantly reduce the risk of gonorrhea, chlamydia, syphilis, hepatitis B, and HIV itself, and they offer partial protection against herpes and HPV by covering some of the skin involved in transmission.
The most effective approach for someone on PrEP combines several layers: consistent condom use when possible, up-to-date vaccinations, regular STI screening at every PrEP follow-up visit, and doxy-PEP if you’re in a group the CDC recommends it for. PrEP removes HIV from the list of things to worry about, but it doesn’t shorten the rest of that list on its own.